and 10 µM) decreased live cell counts, but not survival rate in undifferentiated HL-60 cells and under granulocytic differentiation. Histamine H 4 receptor mRNA was expressed in HL-60 cells, whereas the expression gradually decreased under granulocytic ATRA-differentiation. Thioperamide, a histamine H 4 receptor antagonist or DEVD-FMK, a caspase-3 inhibitor protected clozapine-induced decrease of survival rate, but not of live cell counts. 4-Methylhistamine, a histamine H 4 receptor agonist as well as clozapine decreased survival rate and live cell counts. Conclusion: HL-60 cells under granulocytic differentiation were vulnerable for cytotoxicity of clozapine and would be in vitro assay systems for hematopoietic toxicity. Histamine H 4 receptor is involved in development of clozapine-induced hematopoietic toxicity with apoptosis, and may be one of the target for preventing it in process of granulocytic differentiation. Abstract Objectives: Clozapine is indicated for Treatment Resistant Schizophrenia (TRS) yet only 30-60% of patients will respond to optimum treatment. There have been studies of clozapine augmentation with oral second generation antipsychotics (SGA) with mixed results but no studies considering the combination with long acting injectable (LAI) antipsychotics. This study attempts to establish the efficacy of the combination of clozapine and LAI antipsychotics in TRS. Methods: A mirror-image study design was employed to review health care utilization measures 2 years pre and post combination of clozapine with a LAI (either first generation antipsychotic (FGA) or SGA) in a small sample of patients (N=20) with chronic psychotic disorders followed by the Assertive Community Treatment service in Calgary, Alberta. Results: Paired sample t tests showed a statistically significant reduction in average ED visits in the two years post combination with an average 1.8 fewer ED visits (95%CI = [0.58 to 3.02], p=0.024). There was also a statistically significant reduction in number of hospital admissions in the 2 year post combination with a mean reduction of 0.85 admissions (95%CI = [0.36 to 1.34], p=0.008). There was no statistically significant reduction in hospital bed days between pre-and post-combination. Conclusions: The combination of clozapine and a long acting injectable antipsychotic appears to reduce health care utilization in terms of ED visits and number of hospital admissions. Future research will investigate the effects of this combination on psychopathology and health related quality of life outcomes in this patient population.
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Combination of Clozapine with Long Acting Injectable Antipsychotics in Treatment Resistant Schizophrenia: Preliminary Evidence from Health Care Utilization Indices Rachel Grimminck, MD, FRCPC Toba Oluboka, MD, FRCPC, Manvir Bal, BA, Donna L. Rutherford, BSc, Tolulope Sanjobi, PhD, Helen Yeung, MD, FRCPC Abstract Objectives: Clozapine is indicated for Treatment Resistant Schizophrenia (TRS) yet only 30-60% of patients will respond to optimum treatment. There have been studies of clozapine augmentation with oral second generation antipsychotics (SGA) with mixed results but no studies considering the combination with long acting injectable (LAI) antipsychotics. This study attempts to establish the efficacy of the combination of clozapine and LAI antipsychotics in TRS. Methods: A mirror-image study design was employed to review health care utilization measures 2 years pre and post combination of clozapine with a LAI (either first generation antipsychotic (FGA) or SGA) in a small sample of patients (N=20) with chronic psychotic disorders followed by the Assertive Community Treatment service in Calgary, Alberta. Results: Paired sample t tests showed a statistically significant reduction in average ED visits in the two years post combination with an average 1.8 fewer ED visits (95%CI = [0.58 to 3.02], p=0.024). There was also a statistically significant reduction in number of hospital admissions in the 2 year post combination with a mean reduction of 0.85 admissions (95%CI = [0.36 to 1.34], p=0.008). There was no statistically significant reduction in hospital bed days between pre-and post-combination. Conclusions: The combination of clozapine and a long acting injectable antipsychotic appears to reduce health care utilization in terms of ED visits and number of hospital admissions. Future research will investigate the effects of this combination on psychopathology and health related quality of life outcomes in this patient population.
PM429
Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment Abstract Background: Long-term treatment with antipsychotic drugs in patients with schizophrenia occasionally causes dopamine supersensitivity psychosis (DSP), which is characterized by acute exacerbation of psychiatric symptoms due to discontinuation of antipsychotics, tolerance to the therapeutic effects of antipsychotics, and presence of tardive dyskinesia. Many studies have shown that DSP is attributed to compensatory upregulation of dopamine D 2 receptor (D 2 R) density as a result of chronic and excessive blockade of D 2 Rs by antipsychotics (Iyo et al., 2013) . Objective: Blonanserin (BNS) is an atypical antipsychotic drug, which has high affinity for D 2 R, dopamine D 3 receptor (D 3 R), and 5-HT 2A receptor and weak or very low affinity for other receptors. The present study investigated whether chronic treatment with BNS causes DSP. Method: Male Wistar rats (6-week-old) were orally administered haloperidol (HPD) and BNS, at doses of 1.1 mg/kg and 0.78 mg/kg, respectively, or vehicle twice daily for 28 days. These doses were equivalent to two times the 50% effective doses of HPD and BNS in a methamphetamine-induced hyperlocomotion test in rats, respectively. Seven days after drug discontinuation, a quinpirole (0.5 mg/kg, sc)-induced hyperlocomotion test or a radioligand binding assay using 3 H-raclopride for striatal D 2 R was conducted. We also investigated the effects of chronic treatments with HPD and BNS on D 2 R and D 3 R mRNA levels in five brain regions. Results: Chronic treatment with HPD significantly increased locomotor activity and D 2 R density (i.e. Bmax) compared with vehicle treatment. In contrast, chronic BNS treatment did not affect both locomotor activity and D 2 R density. There were no changes in D 2 R and D 3 R mRNA levels in chronic HPD-and BNStreated groups, respectively.
Conclusion:
The present results suggest that long-term treatment with BNS is less likely to cause DSP compared to treatment with the typical antipsychotic drug, HPD.
